Nu Skin Enterprises, Inc.
NUS NYSE· Wholesale-Drugs, Proprietaries & Druggists' Sundries
Last close · Oct 23, 2026
$4.79
KIRA · Stoqly’s AI analyst, in plain words
- Nu Skin Enterprises, Inc. had $1.5B of revenue in fiscal 2025, down 14.3% on the year before. Over five years, revenue changed −10.5% a year on average.
- Its operating margin was 4.4%, up 13.2 pts: of every 100 in sales, about 4 is left after running the business.
- Nu Skin Enterprises, Inc. made $160M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 2.5% a year.
- Free cash flow was $46.0M in fiscal 2025, 3.1% of revenue.
- Nu Skin Enterprises, Inc. returned $31.9M to shareholders in fiscal 2025, 69% of free cash flow. The diluted share count rose 1.3%.
- Nu Skin Enterprises, Inc. has $7.3M more cash than debt.
Market cap
$233M
P/E
—
Revenue
$1.5B
Net income
$160M
Free cash flow
$46.0M
Operating margin
4.4%
Nu Skin Enterprises, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−14.3%
No. Sales fell 14.3% last year.
Does it make a profit?
10.8%
Yes. It keeps 10.8% of every sale as profit.
Does profit turn into cash?
3.1%
Partly. 3.1% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Nu Skin Enterprises, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 13, 2026
- Legal name
- NU SKIN ENTERPRISES, INC.
- CIK
- 0001021561
Nu Skin Enterprises, Inc. · NUS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $2.7B | $2.2B | $2.0B | $1.7B | $1.5B |
| Revenue growth | 4.4% | −17.4% | −11.5% | −12.0% | −14.3% |
| Gross margin | 75.0% | 71.7% | 68.9% | 68.2% | 69.4% |
| Operating margin | 8.7% | 5.0% | 2.5% | −8.8% | 4.4% |
| Net income | $147M | $105M | $8.6M | −$147M | $160M |
| Net margin | 5.5% | 4.7% | 0.4% | −8.5% | 10.8% |
| Diluted EPS | $2.86 | $2.07 | $0.17 | −$2.95 | $3.18 |
| Cash | |||||
| Cash from operations | $142M | $108M | $119M | $112M | $80.3M |
| Capital expenditure | $68.6M | $59.1M | $58.5M | $41.6M | $34.3M |
| Free cash flow | $73.0M | $49.0M | $60.1M | $70.2M | $46.0M |
| FCF margin | 2.7% | 2.2% | 3.1% | 4.1% | 3.1% |
| Dividends paid | $76.3M | $77.0M | $77.6M | $11.9M | $11.8M |
| Share buybacks | $80.4M | $70.0M | $13.0M | $0.0M | $20.0M |
| Share count change | −2.5% | −1.8% | −1.3% | −0.4% | 1.3% |
| Debt and strength | |||||
| Cash and short-term investments | $355M | $279M | $268M | $198M | $240M |
| Debt incl. finance leases | $384M | $418M | $516M | $404M | $233M |
| Shareholders' equity | $913M | $897M | $822M | $651M | $805M |
| Net debt / EBITDA | 0.1x | 0.8x | 2.1x | — | −0.1x |
| Current ratio | 1.6x | 2.1x | 2.1x | 1.8x | 2.1x |
| Interest coverage | 21.3x | 8.2x | 1.9x | −5.7x | 4.7x |
| Returns and quality | |||||
| Return on capital | 16.3% | 10.9% | 3.0% | −14.1% | 6.8% |
| Return on equity | 16.3% | 11.6% | 1.0% | −19.9% | 22.0% |
| Return on tangible equity | 23.4% | 16.8% | 1.7% | −29.7% | 23.6% |
| Piotroski F-score | 5 | 5 | 5 | 5 | 6 |
| Altman Z'' | 6.2 | 6.3 | 5.8 | 5.0 | 7.4 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$0.1M
3 insiders
Of sales under plans
82%
$0.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Nu Skin Enterprises, Inc. · NUS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.79 a share, the company is worth $233M.
Source: SEC EDGAR XBRL filings (CIK 0001021561). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.